Chiesi Farmaceutici has filed a patent for compounds inhibiting P2X purinoceptor 3, specifically amino quinazoline derivatives. These compounds could potentially treat respiratory diseases like cough, asthma, IPF, and COPD. GlobalData’s report on Chiesi Farmaceutici gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Chiesi Farmaceutici SpA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Chiesi Farmaceutici, Inhalation devices was a key innovation area identified from patents. Chiesi Farmaceutici's grant share as of January 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

A patent application (Publication Number: US20240025880A1) discloses a compound of formula (I) and its various derivatives, including stereoisomers, tautomers, pharmaceutically acceptable salts, and solvates. The compound of formula (I) belongs to a specific group of chemical structures, such as 8-(2,2-difluoroethoxy)-6-(4-fluorophenyl)-N-((6-methylpyridazin-3-yl)methyl)quinazolin-4-amine, among others. These compounds are intended for use in pharmaceutical compositions formulated for oral administration, either alone or in combination with other active ingredients and suitable carriers or excipients.

Furthermore, the patent application claims methods for treating diseases involving P2X3 receptors, particularly respiratory diseases like cough, asthma, idiopathic pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD). The disclosed methods involve administering the pharmaceutical compositions containing the compound of formula (I) to individuals suffering from these conditions. Additionally, a specific method for treating chronic cough is detailed, emphasizing the oral administration of the pharmaceutical composition. Overall, the patent application highlights the potential therapeutic applications of the disclosed compounds in addressing respiratory diseases and conditions associated with P2X3 receptors.

To know more about GlobalData’s detailed insights on Chiesi Farmaceutici, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies